Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 & [18F]PI-2620 or

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03030586` - ADDIA Proof-of-Performance Clinical Study
Withdrawn	`NCT04055532` - Biomarkers in Neurodegenerative Diseases
Recruiting	`NCT05395624` - Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers	Phase 1/Phase 2
Completed	`NCT03518073` - A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease	Phase 2

See also

Status

Clinical Trial

Phase

Recruiting

NCT03030586 - ADDIA Proof-of-Performance Clinical Study

Withdrawn

NCT04055532 - Biomarkers in Neurodegenerative Diseases

Recruiting

NCT05395624 - Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Phase 1/Phase 2

Completed

NCT03518073 - A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04566003
Study type	Interventional
Source	Genentech, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	October 26, 2020
Completion date	June 27, 2023

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms